Akebia Therapeutics (AKBA) Inventory Average (2019 - 2026)

Akebia Therapeutics (AKBA) has 8 years of Inventory Average data on file, last reported at $14.3 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $14.3 million, down 20.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (down 20.48% YoY), and the FY2025 annual result was $15.9 million, changed 0.25% from the prior year.
• Inventory Average declined to $14.3 million in Q1 2026 per AKBA's latest filing, from $17.1 million in the prior quarter.
• Over five years, Inventory Average peaked at $42.7 million in Q3 2022 and troughed at $14.3 million in Q1 2026.
• A 5-year average of $23.8 million and a median of $20.6 million in 2024 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2023 and 2024: Inventory Average tumbled 53.96% in 2023, then grew 19.58% in 2024.
• A 5-year view of Inventory Average shows it stood at $33.4 million in 2022, then plunged by 48.91% to $17.1 million in 2023, then rose by 7.63% to $18.4 million in 2024, then decreased by 6.76% to $17.1 million in 2025, then slipped by 16.49% to $14.3 million in 2026.
• Business Quant data shows AKBA's Inventory Average at $14.3 million in Q1 2026, $17.1 million in Q4 2025, and $17.7 million in Q3 2025.